Cytokinetics Expands Aficamten Data, Showing Cardiac Remodeling Benefits in Non-Obstructive HCM
Event summary
- Cytokinetics presented new aficamten data at the HCMS Scientific Sessions 2026, including late-breaking oral abstracts from ACACIA-HCM and a poster from FOREST-HCM.
- ACACIA-HCM sub-study showed aficamten reduced left ventricular mass index and wall thickness in non-obstructive HCM patients after 36 weeks.
- FOREST-HCM data indicated sustained safety and tolerability of aficamten in obstructive HCM, with rare and reversible cases of reduced LVEF.
- Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.
The big picture
Cytokinetics' latest data positions aficamten as a potential paradigm-shifting therapy for both obstructive and non-obstructive hypertrophic cardiomyopathy. The company is leveraging these results to pursue expanded regulatory approvals, aiming to capture a larger share of the HCM market. With approximately 1 in 350 individuals affected by HCM globally, the strategic significance of these findings extends to a substantial patient population in need of targeted therapies.
What we're watching
- Regulatory Pathway
- Whether Cytokinetics can secure approval for aficamten in non-obstructive HCM by early 2027, expanding its market potential.
- Clinical Efficacy
- How the sustained cardiac remodeling benefits observed in ACACIA-HCM translate into long-term patient outcomes.
- Competitive Positioning
- The pace at which Cytokinetics can differentiate aficamten in a crowded HCM treatment landscape.
